Acelot
Acelot is a biotechnology company focused on developing small molecule therapeutics for challenging targets in diseases with high unmet need, particularly neurodegenerative diseases. Their lead program targets TDP-43 to treat amyotrophic lateral sclerosis (ALS). ACE-2223 is their primary candidate, a small molecule designed to specifically target and disrupt misfolded TDP-43, aiming to restore its normal function and treat the cascade of inflammatory reactions leading to ALS. The company utilizes a platform that integrates novel AI tools, computational chemistry, and assays for *de novo* drug design and optimization of small molecule candidates. Beyond ALS, Acelot is exploring applications for their platform in fronto-temporal dementia, Alzheimer's disease, inclusion body myositis, multiple system atrophy, and dementia with Lewy bodies. They emphasize rigorous science and efficient development, collaborating with experts in disease biology.
Acelot
Acelot is a biotechnology company focused on developing small molecule therapeutics for challenging targets in diseases with high unmet need, particularly neurodegenerative diseases. Their lead program targets TDP-43 to treat amyotrophic lateral sclerosis (ALS). ACE-2223 is their primary candidate, a small molecule designed to specifically target and disrupt misfolded TDP-43, aiming to restore its normal function and treat the cascade of inflammatory reactions leading to ALS. The company utilizes a platform that integrates novel AI tools, computational chemistry, and assays for *de novo* drug design and optimization of small molecule candidates. Beyond ALS, Acelot is exploring applications for their platform in fronto-temporal dementia, Alzheimer's disease, inclusion body myositis, multiple system atrophy, and dementia with Lewy bodies. They emphasize rigorous science and efficient development, collaborating with experts in disease biology.